Critical Analysis: ConvergeOne (CVON) versus China Cord Blood (CO)

ConvergeOne (NASDAQ: CVON) and China Cord Blood (NYSE:CO) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of recent ratings and recommmendations for ConvergeOne and China Cord Blood, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConvergeOne 0 0 3 0 3.00
China Cord Blood 0 0 0 0 N/A

ConvergeOne currently has a consensus price target of $12.00, suggesting a potential upside of 33.19%. Given ConvergeOne’s higher possible upside, analysts plainly believe ConvergeOne is more favorable than China Cord Blood.

Earnings & Valuation

This table compares ConvergeOne and China Cord Blood’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ConvergeOne $918.93 million 2.19 $290,000.00 $0.38 23.71
China Cord Blood $110.41 million 10.71 $18.33 million N/A N/A

China Cord Blood has lower revenue, but higher earnings than ConvergeOne.


This table compares ConvergeOne and China Cord Blood’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ConvergeOne N/A 465.62% 13.29%
China Cord Blood 27.05% 9.05% 4.49%

Institutional & Insider Ownership

5.8% of ConvergeOne shares are held by institutional investors. Comparatively, 22.0% of China Cord Blood shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


ConvergeOne beats China Cord Blood on 5 of the 9 factors compared between the two stocks.

About ConvergeOne

ConvergeOne Holdings, Inc. provides collaboration and technology solutions for large and medium enterprises. It offers cloud solutions, such as C1CX, a collaboration solution spanning unified communications and contact centers with software applications, integration, and professional services; hosted collaboration solutions; and any communications as a service solution. The company also offers collaboration and unified communications, such as applications, conferencing, messaging and presence, mobility and Bring Your Own Device, and telephony services; enterprise applications and software development solutions; and enterprise networking solutions, such as routing and switching, mobility and mobile device management, and wireless. In addition, it offers contact center solutions, such as analytics and reporting, desktop, omnichannel communications, remote agent, social media, cloud connectors and integration software, and workforce optimization and quality monitoring, as well as IVR, self-services, and advanced routing; data center and virtualization solutions, including servers, storage, tools and management, and virtualization; and security solutions, such as firewall, secure socket layer, adaptive security appliance, and risk mitigation. Further, the company provides professional and managed services, such as application, cloud and data, communication, professional voice recording, networking, program management, resiliency, security, and systems and infrastructure. ConvergeOne Holdings, Inc. offers its services through delivery models, such as on-premise; and in private, hybrid, and public clouds, as well as through the ConvergeOne Cloud. It serves banking, finance, education, government, healthcare, hospitality, insurance, manufacturing, media, pharmaceutical, technology, transportation, and utilities industries. It has strategic partnerships with Avaya, Cisco, IBM, Genesys, and Microsoft. The company was founded in 1993 and is headquartered in Eagan, Minnesota.

About China Cord Blood

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants. As of March 31, 2016, the Company had three operating cord blood banks.

Receive News & Ratings for ConvergeOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvergeOne and related companies with's FREE daily email newsletter.

Leave a Reply